Literature DB >> 19705046

The potential impact of new National Osteoporosis Foundation guidance on treatment patterns.

B Dawson-Hughes1, A C Looker, A N A Tosteson, H Johansson, J A Kanis, L J Melton.   

Abstract

UNLABELLED: This analysis of National Health and Nutrition Examination Survey III data describes the prevalence of risk factors for osteoporosis and the proportions of men and postmenopausal women age 50 years and older who are candidates for treatment to lower fracture risk, according to the new FRAX-based National Osteoporosis Foundation Clinician's Guide.
INTRODUCTION: Little information is available on prevalence of osteoporosis risk factors or proportions of US men and women who are potential candidates for treatment.
METHODS: The prevalence of risk factors used in the new National Osteoporosis Foundation (NOF) FRAX-based Guide to the Prevention and Treatment of Osteoporosis was estimated using data from the third National Health and Nutrition Examination Survey (NHANES III). Risk factors not measured in NHANES III were simulated using World Health Organization cohorts. The proportion of US men and postmenopausal women age 50+ years who are treatment candidates by the new NOF Guide were calculated; for non-Hispanic white (NHW) women, the proportion eligible by the new NOF Guide was compared with that based on an earlier NOF Guide.
RESULTS: Twenty percent of men and 37% of women were potential candidates for treatment to prevent fractures by the new NOF Guide. Among NHW women, 53% were potential candidates by the previous NOF Guide compared with 41% by the new guide.
CONCLUSIONS: One fifth of men and 37% of postmenopausal women are eligible for osteoporosis treatment consideration by the new NOF Guide. However, fewer NHW women are eligible by the new guide than by the previous NOF Guide.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19705046     DOI: 10.1007/s00198-009-1034-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  25 in total

1.  Potential risk factors for development of postmenopausal osteoporosis--examined over a 12-year period.

Authors:  M A Hansen; K Overgaard; B J Riis; C Christiansen
Journal:  Osteoporos Int       Date:  1991-02       Impact factor: 4.507

2.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

3.  Trends in hospital care for hip fractures.

Authors:  S H Gehlbach; J S Avrunin; E Puleo
Journal:  Osteoporos Int       Date:  2006-12-05       Impact factor: 4.507

Review 4.  Issues in design, measurement, and analysis for menopause research.

Authors:  S M McKinlay
Journal:  Exp Gerontol       Date:  1994 May-Aug       Impact factor: 4.032

5.  Compliance with osteoporosis medications.

Authors:  Daniel H Solomon; Jerry Avorn; Jeffrey N Katz; Joel S Finkelstein; Marilyn Arnold; Jennifer M Polinski; M Alan Brookhart
Journal:  Arch Intern Med       Date:  2005-11-14

6.  Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.

Authors:  Allison A Hedley; Cynthia L Ogden; Clifford L Johnson; Margaret D Carroll; Lester R Curtin; Katherine M Flegal
Journal:  JAMA       Date:  2004-06-16       Impact factor: 56.272

7.  Toward the 'tipping point': decision aids and informed patient choice.

Authors:  Annette M O'Connor; John E Wennberg; France Legare; Hilary A Llewellyn-Thomas; Benjamin W Moulton; Karen R Sepucha; Andrea G Sodano; Jaime S King
Journal:  Health Aff (Millwood)       Date:  2007 May-Jun       Impact factor: 6.301

8.  Early discontinuation of treatment for osteoporosis.

Authors:  Anna N A Tosteson; Margaret R Grove; Cristina S Hammond; Megan M Moncur; G Thomas Ray; Gwen M Hebert; Alice R Pressman; Bruce Ettinger
Journal:  Am J Med       Date:  2003-08-15       Impact factor: 4.965

9.  Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004.

Authors:  Suzanne M Cadarette; Jeffrey N Katz; M Alan Brookhart; Raisa Levin; Margaret R Stedman; Niteesh K Choudhry; Daniel H Solomon
Journal:  J Rheumatol       Date:  2007-12-01       Impact factor: 4.666

10.  Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004.

Authors:  Anne C Looker; Christine M Pfeiffer; David A Lacher; Rosemary L Schleicher; Mary Frances Picciano; Elizabeth A Yetley
Journal:  Am J Clin Nutr       Date:  2008-12       Impact factor: 7.045

View more
  38 in total

1.  Trends and Determinants of Osteoporosis Treatment and Screening in Patients With Rheumatoid Arthritis Compared to Osteoarthritis.

Authors:  Gulsen Ozen; Diane L Kamen; Ted R Mikuls; Bryant R England; Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-03-11       Impact factor: 4.794

Review 2.  Type 2 diabetes and bone fractures.

Authors:  Kendall F Moseley
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-04       Impact factor: 3.243

Review 3.  Assessment of fracture risk.

Authors:  Sanford Baim; William D Leslie
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

4.  A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).

Authors:  J A Kanis; H Johansson; A Oden; E V McCloskey
Journal:  Osteoporos Int       Date:  2011-02-02       Impact factor: 4.507

5.  Predicting hip and major osteoporotic fractures using administrative data.

Authors:  Huifeng Yun; Elizabeth Delzell; Kristine E Ensrud; Meredith L Kilgore; David Becker; Michael A Morrisey; Jeffrey R Curtis
Journal:  Arch Intern Med       Date:  2010-11-22

6.  Is lower income associated with an increased likelihood of qualification for treatment for osteoporosis in Canadian women?

Authors:  S L Brennan; W D Leslie; L M Lix
Journal:  Osteoporos Int       Date:  2013-08-02       Impact factor: 4.507

7.  Hip fracture risk in older US adults by treatment eligibility status based on new National Osteoporosis Foundation guidance.

Authors:  A C Looker; B Dawson-Hughes; A N A Tosteson; H Johansson; J A Kanis; L J Melton
Journal:  Osteoporos Int       Date:  2010-05-18       Impact factor: 4.507

8.  Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement.

Authors:  Sherita Hill Golden; Arleen Brown; Jane A Cauley; Marshall H Chin; Tiffany L Gary-Webb; Catherine Kim; Julie Ann Sosa; Anne E Sumner; Blair Anton
Journal:  J Clin Endocrinol Metab       Date:  2012-06-22       Impact factor: 5.958

Review 9.  A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.

Authors:  John A Kanis; Nicholas C Harvey; Cyrus Cooper; Helena Johansson; Anders Odén; Eugene V McCloskey
Journal:  Arch Osteoporos       Date:  2016-07-27       Impact factor: 2.617

10.  Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study.

Authors:  S D Berry; D P Kiel; M G Donaldson; S R Cummings; J A Kanis; H Johansson; E J Samelson
Journal:  Osteoporos Int       Date:  2010-01       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.